Stockscreener 앱 받기
0.312
5.45%
-0.018
시장 영업 전:
.31
-0.002
-0.64%
Glucotrack Inc 주식(GCTK)의 최신 뉴스
GCTK Stock Is Soaring Today — What Is Fueling The Surge? - Stocktwits
GlucoTrack Inc (GCTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to sales forward of GlucoTrack, Inc. – NASDAQ:GCTK - TradingView
Price to book forward of GlucoTrack, Inc. – NASDAQ:GCTK - TradingView
GlucoTrack Inc (GCTK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GlucoTrack Inc (GCTK) Institutional Confidence - TradingKey
GlucoTrack Inc (GCTK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GlucoTrack Inc (GCTK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GlucoTrack Inc (GCTK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GlucoTrack Inc (GCTK) Valuation: PE, PB & Fair Value Analysis - TradingKey
GlucoTrack Inc (GCTK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GlucoTrack Inc (GCTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Glucotrack (NASDAQ: GCTK) seeks reverse split, warrant repricing and auditor ratification - Stock Titan
EBIT per share of GlucoTrack, Inc. – NASDAQ:GCTK - TradingView
GLUCOTRACK INC (GCTK) Stock Chart - ChartMill
GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
Glucotrack CEO explains tech behind long-term CBGM implant - Drug Delivery Business
GCTKGlucoTrack Inc Stock Price and Quote - Finviz
Glucotrack Inc Highlights Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association 2026 Scientific Sessions - marketscreener.com
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions - The Manila Times
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions - Moomoo
Implantable glucose sensor designed for multi-year use without wearables - Stock Titan
GlucoTrack Inc. (GCTK) Surges 8%: Testing Key Resistance at $0.53PCR Spike - The Legal Advocate
GlucoTrack Inc. (GCTK) Rallies 8.23% as Shares Test Key Resistance LevelBlock Trade Flow - thelegaladvocate.com
GlucoTrack Inc. (GCTK) Rebounds Sharply: Bullish Momentum Building Above SupportContinuation Pattern Picks - The Legal Advocate
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
GlucoTrack Faces Multiple Nasdaq Deficiency Notices, Delisting Risk - TipRanks
Glucotrack receives Nasdaq delisting notice over listing rule deficiencies By Investing.com - Investing.com South Africa
Glucotrack receives Nasdaq delisting notice over listing rule deficiencies - Investing.com
Glucotrack Received Notice of Delisting - TradingView
Glucotrack (GCTK) cited for bid price and equity Nasdaq deficiencies - Stock Titan
Armistice Capital (GCTK) reports 102,115 shares, 4.99% ownership - Stock Titan
Glucotrack Reports Q1 2026 Results and Advances IDE Submission for Implantable Glucose Monitor - Minichart
Glucotrack's 3-Year CGM Aims to Revolutionize Diabetes Management - BriefGlance
TradingKey - TradingKey
Glucotrack 1Q Loss/Shr $2.65 >GCTK - Moomoo
Glucotrack Reports Q1 2026 Net Loss of $4.3M, Cash $3.9M, Files IDE for Implantable CBGM - TradingView
Glucotrack, Inc. Q1 2026: Net loss $(4.33M), EPS $(2.65) — 10-Q Summary - TradingView
Glucotrack, Inc. Submits IDE Application to FDA for Implantable Continuous Blood Glucose Monitoring System and Reports Q1 2026 Financial Results - Quiver Quantitative
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
GlucoTrack, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Glucotrack (GCTK) posts Q1 loss as cash tightens and Nasdaq flags delisting - Stock Titan
Glucotrack (NASDAQ: GCTK) Q1 2026 results, IDE filing and cash runway - Stock Titan
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewswire Inc.
GlucoTrack Stock Short Interest Rises to 59.4% - Moomoo
GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why - MSN
What you need to know before buying GlucoTrack (GCTK) (+0.76%) 2026-05-08Mid Cap Momentum - newser.com
How GlucoTrack (GCTK) maintains its asset base | GCTK: GlucoTrack Q Results Lack Revenue, EPS DataFinancial Summary - newser.com
GlucoTrack Files IDE for Implantable Glucose Monitor - TipRanks
0.09%
0.52%
자본화:
|
볼륨(24시간):